← All stocks

Roivant Sciences Ltd.

ROIV Scheduled selling only

CIK 0001635088 #653 in the set updated 17 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$35.66M

$0.00 on a plan · $35.66M straight out of an exercise

Sold at will

$0.00

0 of 9 sales

Net

−$35.66M

$0.00 against sales at will

By person

15 insiders · 9 transactions

916×

Matthew Gline holds 916 times base salary in stock. $664.73M of shares against $725.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Gline last reported holding, valued at $39.90, the price Common Shares was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Sukhatme Mayukh

President & CIO

—

$27.71M (6) scheduled

−$27.71M

18,630,739

2.58%

$743.37M

−17.2%

Venker Eric

President & Immunovant CEO

—

$7.15M (2) scheduled

−$7.15M

1,599,154

0.2214%

$63.81M

+150.1%

Fitzgerald Meghan

Director

—

$798.00K (1) scheduled

−$798.00K

41,220

0.0057%

$1.64M

+40.3%

Ramaswamy Vivek

10% owner

—

47,011,612

6.51%

$1.88B

−12.0%

Gold Daniel Allen

Director

—

22,649,927

3.14%

$903.73M

−67.4%

Gline Matthew

CEO

—

16,659,945

2.31%

$664.73M

−9.0%

MANCHESTER KEITH S

Director

—

15,437,569

2.14%

$615.96M

−60.6%

QVT Financial LP entity

Director by Deputization

—

13,689,166

1.90%

$546.20M

−76.0%

Torti Frank

President and Vant Chair

—

13,536,202

1.87%

$540.09M

—

Pulik Richard

CFO

—

271,810

0.0376%

$10.85M

−5.9%

Kumar Rakhi

Chief Accounting Officer

—

162,306

0.0225%

$6.48M

−23.6%

Oren Ilan

Director

—

118,626

0.0164%

$4.73M

+24.1%

Humes Jennifer

Chief Accounting Officer

—

109,782

0.0152%

$4.38M

—

MOMTAZEE JAMES C

Director

—

106,905

0.0148%

$4.27M

+15.7%

Epperly Melissa B,

Director

—

14,838

0.0021%

$592.04K

−59.3%

Roivant Sciences Ltd.

By person

Individual transactions

What was left out